Sign in
Taking people in South KoreaNo phase

SGLT2 Inhibitors in Type 2 Diabetes After Acute Heart Attack

Observes SGLT2 inhibitor drug use in adults with type 2 diabetes and recent heart attack.

Key facts

Who runs it
Kiyuk Chang
Where
Seoul, South KoreaSee the site
Trial code
Registry title
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Status
Recruiting
People taking part
1,000 people, planned
Started
1 Aug 2020
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • SGLT2 inhibitor
Record updated
3 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who had a heart attack treated with a procedure to open the heart arteries (PCI), and who started an SGLT2 inhibitor medicine around that time.

Age
19 years and older
Sex
All sexes can join.
Disease stage
Acute myocardial infarction (heart attack) treated with percutaneous coronary intervention (PCI), together with type 2 diabetes mellitus.
Earlier treatment
Must have started an SGLT2 inhibitor less than 1 month before or after the PCI. Must not have used an SGLT2 inhibitor before.

Main reasons for not taking part

  • Type 1 diabetes
  • Users of insulin or GLP-1 analogue medicines
  • Previous users of SGLT2 inhibitors
  • Pregnancy

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Acute myocardial infarction who were treated with percutaneous coronary intervention
  • Type 2 diabetes mellitus
  • Started SGLT2 inhibitors <1 month before/after PCI

Who cannot take part

  • Previous users of SGLT2 inhibitors
  • Type 1 diabetes mellitus
  • Insulin / GLP-1 analogue users
  • Pregnancy

Where in South Korea

  • Seoul St. Mary's HospitalSeoul, South KoreaContact: Kiyuk ChangTaking people

About the trial

What the trial wants to find out

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.

Read full original descriptionShow less

The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

The group in the trial

  • SGLT-2 inhibitor

    Patients with naive use of SGLT-2 inhibitors after PCI

    Treatment: SGLT2 inhibitor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Plain-language title
SGLT2 Inhibitors in Type 2 Diabetes After Acute Heart AttackGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 January 2025